Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Remember this

<< Previous

Bullboard Posts

Next >>

Comment by jimmyhorizonon Jul 26, 2022 3:14am

167 Views

Post# 34850115

RE:RE:RE:RE:RE:Remember this

numbers again:

Investor-presentation Jan 31, 2016:

2016E - Upfront payment of $90M in Q2 (**)
2019E - Milestone payment of $98M (**)
2020E - Ongoing royalties totaling $715M (**)

Investor-presentation July 8, 2016

2016E - Upfront payment of $90M in Q3 (**)
2019E - Milestone payment of $98M (**)
2020E - Ongoing royalties totaling $715M (**)

Investor-presentation Nov 1, 2016

2016E - Upfront payment of $90M in Q4 (**)
2019E - Milestone payment of $100M (**)
2020E - Ongoing royalties totaling $1B (**)

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023